<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment protocols for hepatobiliary cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment protocols for hepatobiliary cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment protocols for hepatobiliary cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tim Brenner, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shrina Duggal, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jim Natale, PharmD, BCOP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard M Goldberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1090276">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with biliary cancer and hepatocellular cancer (HCC).
         <strong>
          This is
         </strong>
         <strong>
          not an exhaustive list
         </strong>
         ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with hepatobiliary cancer. Additional regimens may be added over time, particularly as treatment for hepatobiliary cancer evolves.
        </p>
        <p>
         This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with hepatobiliary cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2524.html" rel="external">
          "Systemic therapy for advanced cholangiocarcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2499.html" rel="external">
          "Treatment of advanced, unresectable gallbladder cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2506.html" rel="external">
          "Ampullary carcinoma: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2486.html" rel="external">
          "Systemic treatment for advanced hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2525.html" rel="external">
          "Prognosis and adjuvant treatment for localized, resected gallbladder cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2467.html" rel="external">
          "Adjuvant and neoadjuvant therapy for localized cholangiocarcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.
        </p>
        <p class="headingAnchor" id="H1090199">
         <span class="h1">
          REGIMENS
         </span>
        </p>
        <p class="headingAnchor" id="H607000108">
         <span class="h2">
          Biliary or hepatocellular cancer (HCC)
         </span>
        </p>
        <p class="headingAnchor" id="H934552054">
         <span class="h3">
          Short-term infusional fluorouracil plus leucovorin for advanced gastrointestinal cancer (modified de Gramont schedule)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef65525" href="/z/d/graphic/65525.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="headingAnchor" id="H273751465">
         <span class="h3">
          Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="headingAnchor" id="H607000131">
         <span class="h3">
          Capecitabine and oxaliplatin for locally advanced or metastatic HCC or biliary cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef89431" href="/z/d/graphic/89431.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="headingAnchor" id="H607000161">
         <span class="h2">
          Bilary tract cancer
         </span>
        </p>
        <p class="headingAnchor" id="H934552083">
         <span class="h3">
          Single agent gemcitabine for adjuvant treatment of biliary tract cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef81436" href="/z/d/graphic/81436.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p class="headingAnchor" id="H3458436164">
         <span class="h3">
          Gemcitabine and capecitabine (GEMCAP) followed by concurrent capecitabine and radiotherapy for adjuvant therapy of biliary tract cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef107377" href="/z/d/graphic/107377.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1090566">
         <span class="h3">
          Single agent gemcitabine for metastatic biliary tract cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef60330" href="/z/d/graphic/60330.html" rel="external">
          table 6
         </a>
         )
        </p>
        <p class="headingAnchor" id="H607000198">
         <span class="h3">
          Gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef89633" href="/z/d/graphic/89633.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p class="headingAnchor" id="H607000264">
         <span class="h3">
          Gemcitabine and oxaliplatin (GEMOX) for locally advanced or metastatic biliary tract cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef90451" href="/z/d/graphic/90451.html" rel="external">
          table 8
         </a>
         )
        </p>
        <p class="headingAnchor" id="H4250970826">
         <span class="h3">
          Modified gemcitabine and oxaliplatin (GEMOX) for advanced gallbladder cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef111904" href="/z/d/graphic/111904.html" rel="external">
          table 9
         </a>
         )
        </p>
        <p class="headingAnchor" id="H490689721">
         <span class="h3">
          Gemcitabine and capecitabine (GEMCAP) for advanced biliary tract cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef103038" href="/z/d/graphic/103038.html" rel="external">
          table 10
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1509180510">
         <span class="h3">
          Gemcitabine plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel) for advanced pancreatic and biliary cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef89668" href="/z/d/graphic/89668.html" rel="external">
          table 11
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1046579022">
         <span class="h3">
          FOLFIRI (fluorouracil plus leucovorin and irinotecan) plus bevacizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef64505" href="/z/d/graphic/64505.html" rel="external">
          table 12
         </a>
         )
        </p>
        <p class="headingAnchor" id="H607000227">
         <span class="h2">
          Hepatocellular cancer (HCC)
         </span>
        </p>
        <p class="headingAnchor" id="H279079332">
         <span class="h3">
          Gemcitabine and pegylated liposomal doxorubicin for advanced HCC
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef89985" href="/z/d/graphic/89985.html" rel="external">
          table 13
         </a>
         )
        </p>
        <p class="headingAnchor" id="H27454953">
         <span class="h3">
          Gemcitabine and oxaliplatin (GEMOX) for advanced HCC
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef89385" href="/z/d/graphic/89385.html" rel="external">
          table 14
         </a>
         )
        </p>
        <p class="headingAnchor" id="H726187338">
         <span class="h3">
          Pembrolizumab monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 15
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1313668318">
         <span class="h3">
          Nivolumab monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">
          table 16
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2977551738">
         <span class="h3">
          Nivolumab plus ipilimumab for advanced HCC
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef131342" href="/z/d/graphic/131342.html" rel="external">
          table 17
         </a>
         )
        </p>
        <p class="headingAnchor" id="H3863990989">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div id="topicVersionRevision">
        Topic 85683 Version 30.0
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
